Inhibits Proliferation of
Human Airway Smooth Muscle Cells
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
We hypothesized that an atypical isoform of protein kinase
(PK) C, PKC-
, is essential for proliferation of human airway
smooth muscle (HASM) cells in primary culture. Recombinant
replication-deficient E1-deleted adenoviruses (100 plaque-forming units [pfu]/cell) expressing the antisense of PKC-
and
the wild-type PKC-
(Ad-CMV-PKC-
) were added to actively
growing cells that were subsequently incubated for 48 h in
platelet-derived growth factor (PDGF) 40 ng/mL or 10% fetal
bovine serum (FBS). Expression of the antisense at a virus concentration of 100 pfu/cell produced a significant (n = 3, P < 0.05) decrease in the mean manual cell count in the presence of PDGF to 37 ± 5% relative to that in cells with no virus
(100%), whereas in cells infected with virus containing no
construct, this figure was 102 ± 13%. The increase in cell
number in response to FBS, however, was not affected by the
presence of the antisense. Corresponding values for cells in
10% FBS were 100 ± 22%, 85 ± 22%, and 122 ± 18%. Western blotting revealed decreased levels of PKC-
protein, but
not PKC-
or PKC-
protein, in cells infected with the antisense when compared with levels in control cells. Thus, in
HASM cells, PKC-
is involved in proliferation in response to
PDGF, but not in response to FBS, for which alternate signal transduction pathways independent of PKC-
must exist.
| |
Introduction |
|---|
|
|
|---|
Protein kinase (PK) C is a serine threonine-specific kinase that plays diverse roles in a number of cellular events. Our previous work has shown that PKC is involved in the regulation of tone of airway smooth muscle (ASM) (1, 2). Low concentrations of phorbol esters such as phorbol dibutyrate stimulate endogenous PKC to produce relaxation, and higher concentrations produce a contractile response (2). PKC is also implicated in cell replication (3), and evidence for this exists in ASM. Activation of PKC by phorbol esters stimulates proliferation in human ASM (HASM) (4), and specific inhibitors such as RO31-8220 produce inhibition of growth induced by platelet-derived growth factor (PDGF) (5).
Rather than a single enzyme, PKC consists of a family
of 12 isoforms that fall into three categories (6) according
to their substrate specificities and cofactor requirements
(7), viz, conventional, or calcium- and diacylglycerol-dependent, (PKC-
, -
I, -
II, and -
); novel, or calcium-independent (PKC-
, -
, -
, and -
); and the atypical isoforms
such as PKC-
, -
/
. Recently, we (8, 9) and others (10, 11)
have described the isoforms present in the ASM of a number of species, including humans (9). Isoforms from each
of these three groups were represented in the species studied, although there did appear to be specie differences. The presence of multiple isoforms of PKC in these tissues
suggests diverse roles. There is evidence to indicate that
individual isoforms may be linked to specific functions (3,
12) and that expression may be altered in disease states
(18). PKC-
, an atypical isoform, has been linked specifically to cell proliferation, and indeed, we have found that
upregulation of PKC-
protein occurs in HASM cells stimulated to proliferate with fetal bovine serum (FBS) or
PDGF (9). In the current study, we used adenoviral-mediated expression of an antisense of PKC-
to investigate
whether this upregulation of PKC-
is the cause or a consequence of ASM cell proliferation.
| |
Methods |
|---|
|
|
|---|
Cell Isolation and Culture
HASM cells were cultured by the method of Johnson and colleagues (19). Human lung was obtained from eight patients. Four of these were undergoing transplantation: one for cystic fibrosis, one for lymphangiomyomatosis, and two for emphysema. Two patients were undergoing lung resection for malignant pulmonary
lesions. One patient was a donor whose lungs had been subjected
to trauma and were thus unsuitable for transplantation, and one
was undergoing diagnostic biopsy. Explants of ASM were dissected from large bronchial airways (5 to 15 mm diameter) or biopsies and incubated in Dulbecco's modified Eagle's medium supplemented with 1% penicillin/streptomycin/fungizone (Life
Technologies, Mulgrave, Australia) and 10% FBS (Life Technologies). Flasks were kept in incubators at 37°C in humidified air
containing 5% CO2. Smooth muscle cells were grown to confluence from the explants and used for experiments between passages 4 and 7. Cultures were confirmed as pure smooth muscle
cells by fluorescent staining with monoclonal antibody specific to
-smooth-muscle actin and calponin (Sigma, St. Louis, MO).
Preparation of Recombinant Adenovirus
PKC-
complementary DNA (EMBL Ac. No. M94632; a kind
gift from H. Mischak, Laboratory of Genetics, National Cancer
Institute, Bethesda, MD) (20) was subcloned from pUC19 (by a
HindIII/XbaI digest which was then blunt-ended) into the
EcoRV site of pXCMV. pXCMV is an adenoviral shuttle plasmid
generated by subcloning the NruI/DraIII digested and blunted
expression cassette from pRcCMV (Invitrogen, Carlsbad, CA)
into XbaI digested and blunted pXCX3 (pXCX3 was derived
from pXCX2 [21]). The wild-type and antisense full-length double-stranded DNA clones generated were screened for orientation by restriction digest mapping and the appropriate wild-type
and antisense clones were isolated. Recombinant adenovirus was
prepared essentially as described by Graham and Prevec (22). Cesium chloride-purified plasmid containing the pXCMV PKC-
antisense gene cassette was cotransfected with pJM17 in a ratio of
1:1 using calcium phosphate transfection. Control virus MX17
was constructed by recombination between pXCX2 and pJM17;
it does not contain a gene cassette. Transfection was carried out
only in low-passage (< 50) HEK 293 cells and once transfected,
the HEK cells were maintained in 0.5% agarose and 1× culture
medium. Recombinant viruses were isolated 1 to 2 wk later as
single plaques and amplified by reinfecting confluent monolayers
of HEK 293 cells. Recombinant viruses were characterized by
preparing lysates of cells that showed signs of cytopathic effect 3 to 7 d after the second round of infection. Proteins were separated by 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis and transferred to nitrocellulose membrane for
immunoblotting with anti-PKC-
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) to identify suitable recombinant viral
clones with reduced expression of PKC-
. Medium from the 35-mm dish was used in further rounds of amplification to generate stock virus, which was purified by cesium chloride gradient.
Plaque assays were performed in HEK 293 cells to determine the
titer (plaque-forming units [pfu]/mL) of these stocks.
Measurement of Efficiency and Toxicity of Adenoviral Infection
We used an adenovirus expressing a humanized mutant of green fluorescent protein (GFP), Ad-EF1-GFP20 (23), or CMV-GFP20 to examine the efficiency of adenoviral infection of HASM cells. In these experiments, cells grown on coverslips were infected with 0 or 100 pfu/cell Ad-EF1-GFP20 or CMV-GFP20 and quiesced with 1% FBS for 24 h. We have previously shown that after 24 h in 1% FBS, > 80% of the cells are in G0/G1 (24). Cells were grown in 10% FBS for 48 h and then examined by fluorescence microscopy to ascertain that expression of GFP was uniform. To examine whether infection with adenovirus affected normal proliferation of cells, cells were grown, infected, and quiesced as described earlier, although in six-well culture plates. Cells were then grown in 1, 5, and 10% FBS for 48 h before they were removed from the plates by trypsinization and counted manually.
Proliferation Studies and Antisense Adenoviral Infection
Cells were subcultured into six-well (proliferation studies) or 12-well (antisense adenovirus infection) culture plates at a density of 1 × 104 cells/cm2 and grown for 3 d in 10% FBS. Adenovirus with or without the antisense construct was then added to cultures at 10 or 100 pfu/cell for 24 h. This was followed by a 24-h period of quiescence in 1% FBS and then a 48-h exposure to either 10% FBS, 40 ng/mL PDGF, or 1% FBS. Cells were removed from the plates by trypsinization, and manual cell counts were performed. All treatments were done in triplicate, and means from individual experiments (patients) were pooled for statistical analysis.
Immunoblotting
For detection of PKC-
by immunoblotting (8), control cells and
cells infected with adenovirus (100 pfu/cell) were subcultured into 24-well culture plates. After infection, cells were stimulated with 40 ng/mL PDGF for 24 h and then extracted directly into
SDS loading buffer (4% SDS; 15% glycerol; 62.5 mM Tris-HCl,
pH 6.8; 0.005% bromophenol blue; and 200 mM dithiothreitol),
then mixed 1:1 with water.
For electrophoresis, samples were resolved on SDS polyacrylamide (10%) gels using a Bio-Rad Mini Protean apparatus. Proteins were then electroblotted onto nitrocellulose membranes. Specific polyclonal antibodies directed against PKC-
, PKC-
, and
PKC-
were obtained from Santa Cruz Biotechnology.
Western blots were developed by the ECL system (Amersham Pharmacia Biotech, Little Chalfront, UK), using the isoform-specific primary antibody, and secondary antibody obtained from Sigma. Relative signal intensities were quantified by densitometry.
Analysis of Results
To obtain mean results from cells, which were derived from different patients and exhibited a wide range of growth rates, cell counts were expressed on a scale relative to that obtained in the presence of 1% FBS but in the absence of virus. Values were compared with the use of one-factor analysis of variance with repeated measures and Fisher's PLSD. Levels of significance were set at P < 0.05.
| |
Results |
|---|
|
|
|---|
At a virus concentration of 100 pfu/cell, all cells were found to express high levels of GFP, although the levels of expression varied from cell to cell (23). Growth curves constructed for cells from the same patient stimulated with 10% FBS (19) in the presence of virus at 0 and 100 pfu/cell revealed that the increase in viable cell counts was not affected by 100 pfu/cell (Figure 1). Thus, concentrations of 10 and 100 pfu/cell were chosen for subsequent experiments.
|
In separate experiments, the presence of the antisense
PKC-
adenovirus at 10 and 100 pfu/cell significantly reduced proliferation produced by 48 h exposure to 40 ng/mL
PDGF, compared with controls treated with no adenovirus or adenovirus expressing no transgene (Ad-MX17) (Figure 2). The amount of 10 pfu/cell appeared to produce a
greater inhibition of growth, although the responses to 10 and 100 pfu/cell were not significantly different from each
other.
|
None of the concentrations of antisense virus used produced any effect on FBS-induced responses. In addition,
infection of the cells with the adenovirus expressing wild-type PKC-
(100 pfu/cell) produced no change in cell proliferation induced by 10% FBS or 40 ng/ml PDGF. Finally,
expression of the antisense had no effect on cells made
quiescent by incubation in 1% FBS, indicating that it does
not have a nonspecific effect on cell viability. These results
are shown in Figure 2. The relative mean cell counts after
stimulation with PDGF in cells containing the antisense
(100 pfu/cell), wild-type (100 pfu/cell), virus control with
no insert (100 pfu/cell), and no virus were 37 ± 5, 67 ± 18, 102 ± 13 (mean values ± standard error of the mean [SEM]) and 100%, respectively. The corresponding values for cells
stimulated with 10% FBS were 100 ± 22, 67 ± 24, 122 ± 18, and 85 ± 22%, respectively. The value for cells expressing
the antisense and stimulated with PDGF was significantly
different from each of the other treatment categories (n = 3, P < 0.05). Counts in cells containing the wild-type construct were not significantly different from control values.
Immunoblots revealed expression of PKC-
protein in
all cells, whether they were infected with viruses (at 100 pfu/cell) expressing wild-type PKC-
or antisense PKC-
,
or virus with no construct. However, the density of the immunoblots was decreased by 47 ± 16% in cells that contained antisense PKC-
viruses when compared with cells
that contained no virus (Figure 3). Immunoblots for PKC-
and PKC-
, however, were not significantly decreased (88 ± 12 and 98 ± 22% of control, respectively; n = 3) in the
presence of the PKC-
antisense (Figure 3).
|
| |
Discussion |
|---|
|
|
|---|
This study demonstrated that an antisense of PKC-
can
inhibit the proliferation of HASM cells stimulated with
PDGF, but not proliferation induced by FBS. That the response is isoform-specific was borne out by the finding
that the amount of protein for PKC-
in cells expressing
the antisense was reduced, whereas that for two other isoforms, one calcium-dependent and the other calcium-independent
respectively, PKC-
and PKC-
was not affected. In addition, our results demonstrate that adenoviruses
can be successfully used to carry sense and antisense genes
into HASM cells with high efficiency.
Our previous studies showed that, in HASM cells proliferating in response to PDGF or FBS, there was a significant increase in the amount of PKC-
protein (9). Moreover, this did not occur for PKC-
, -
I, -
II, -
, -
, -
-
, or
-
in response to the same stimuli. In addition, prostaglandin (PG) E2, which inhibits proliferation (19), almost completely inhibited this increase in PKC-
protein. The results
of the present study increase the strength of the evidence
for a causal relationship between PKC-
and PDGF-induced
mitogenesis in HASM cells and also show that the increase
in PKC-
is required for cell proliferation in response to
PDGF rather than being a consequence of proliferation. The fact that FBS-induced proliferation was unaffected by
the presence of the antisense indicates that PKC-
is not a
universal mediator of HASM proliferation and may be
critical only in some tyrosine kinase receptor-mediated
signal transduction pathways. In addition, in our previous
study (9), although FBS and PDGF both produced increases in PKC-
protein and both induced proliferation, the increase in PKC-
in response to PDGF was demonstrable in both cytosolic and membrane fractions of the
cells. This was not the case for FBS, which increased PKC-
protein only in the cytosolic fraction. The absence of an increase in the active membrane fraction may explain the
lack of effect of the PKC-
antisense on FBS-induced proliferation in the current experiments.
In the present study, the antisense of PKC-
reduced
PDGF-induced mitogenesis by 63% compared with control.
Thus, although there was significant inhibition of PDGF-mediated responses, mitogenesis was not completely abolished.
It is likely that even though all cells may have been infected
by the adenovirus, the levels of expression of the transgene
varied from cell to cell (23). High levels of antisense expression may be necessary to achieve full inhibition. Lower levels
of expression in some could lead to only partial inhibition,
and this may be the most likely explanation for our findings.
The signal transduction events upstream and downstream
of PKC-
have been studied in a variety of cell types, but
the placement of PKC-
in these pathways remains unclear. In response to PDGF, PKC-
has been reported to
directly activate Raf-1 (25) or to be directly activated by
Ras, which can also activate c-Raf. Activation of Ras is
critical for PKC-
activation (26), and phosphorylation by
PIP3-dependent kinase (PDK) (27) has also been shown
to activate PKC-
. In pathways leading to gene expression,
activated PKC-
inactivates I
B leading to regulation of
nuclear factor-
B (28). These pathways have not been defined in HASM cells and, as we (8) and others (29) have
shown, distribution of PKC isoforms as well as their involvement in mitogenesis is markedly different in animal
airways. Our antisense data in the present study would indicate that PKC-
is not an essential component of FBS-induced proliferation and this may be because G-protein-
coupled pathways are involved in this response. However,
this would conflict with the findings of Ammit and colleagues (30), who reported that p21ras is a common step in
mitogenic pathways arising from stimulation of both receptor tyrosine kinase and G-protein-coupled receptors.
It is difficult to speculate on the nature of pathways that
could be independent of PKC-
and thus account for the lack
of effect of the antisense on FBS-induced proliferation.
Whether FBS stimulates other kinases such as p70S6K, which
are independent of PKC-
(31), is not known. Knowledge of
the pathways leading to HASM proliferation is incomplete
and marked specie differences abrogate extrapolation from
animal models. We have shown in previous studies that PGE2
and heparin both inhibit HASM mitogenesis (19), the former
most likely via a cyclic adenosine monophosphate-dependent
mechanism (24) and the latter by an as-yet-undelineated pathway. The events which occur distal to tyrosine kinase and
proximal to cyclin D are likely to involve the MEK/ERK pathway. Recently, it has been reported that the GRB2/SOS/Ras/ Raf pathway and the PI3K/PDK-1/PKC-
pathways
hitherto
considered functionally separate
are jointly required for
ERK activation in rat adipocytes (32). Whether this holds true
for proliferation in HASM cells requires investigation.
In the present study the PKC-
antisense produced a
marked decrease in the levels of PKC-
protein as detected by immunoblotting, but did not decrease the protein level for two other isoforms, viz, PKC-
and PKC-
. This contrasts with the findings from some previous studies that used a dominant negative mutant of PKC-
and
found that it inhibited activated PKC-
as well as PKC-
(33). Use of the antisense approach in our study presumably avoids the potential for a dominant negative mutant
to antagonize upstream substrates for other kinases.
The evidence from the current study for an association
between PKC-
and mitogenesis raises the possibility for selective inhibition of this isoform. Such an example already
exists, in that inhibition of PKC-
with a novel, orally active
inhibitor ameliorates vascular dysfunction in a rat model of
diabetes (34). Our study examined the relationship between
PKC-
and mitogenesis in HASM cells, but these were not
obtained from patients with asthma. If it is possible in the
future to demonstrate this relationship in asthmatic cells,
then it would be conceivable that new pharmacologic or antisense approaches could be used to inhibit the ASM hyperplasia that is an unwanted feature of asthmatic airways.
| |
Footnotes |
|---|
Address correspondence to: Prof. Judith L. Black, MBBS, Ph.D., Dept. of Pharmacology, University of Sydney, NSW 2006, Australia. E-mail: judblack{at}pharmacol.usyd.edu.au
(Received in original form April 4, 2000 and in revised form June 1, 2000).
Acknowledgments: The authors thank the surgical and pathology staff of the following hospitals for the supply of human lung tissue: Royal Prince Alfred, St. Vincent's, Concord, Royal North Shore, and Strathfield Private. The authors also acknowledge the collaborative effort of the cardiopulmonary transplant team at St. Vincent's Hospital. This work was supported by the National Health and Medical Research Council of Australia and the Community Health and Antituberculosis Association.
Abbreviations ASM, airway smooth muscle; FBS, fetal bovine serum; GFP, green fluorescent protein; HASM, human ASM; PDGF, platelet-derived growth factor; pfu, plaque-forming units; PK, protein kinase; SDS, sodium dodecyl sulfate.
| |
References |
|---|
|
|
|---|
1. Yang, K. X. F., and J. L. Black. 1995. The involvement of protein kinase C in the contraction of human airway smooth-muscle. Eur. J. Pharmacol. 275: 283-289 [Medline].
2. Yang, K. X. F., and J. L. Black. 1996. Protein kinase C induced changes in human airway smooth-muscle tone: the effects of calcium and sodium transport. Eur. J. Pharmacol. 315: 65-71 [Medline].
3.
Berra, E.,
M. T. Diaz-Meco,
I. Dominguez,
M. M. Municio,
L. Sanz,
J. Lozano,
R. S. Chapkin, and
J. Moscat.
1993.
Protein kinase
isoform is critical
for mitogenic signal transduction.
Cell
74:
555-563
[Medline].
4. Panettieri, R. A. 1994. Airway smooth-muscle cell growth and proliferation. In Airway Smooth Muscle: Development and Regulation of Contractility. D. Raeburn and M. A. Giembycz, editors. Birkhauser, Verlag, Basel. 41-68.
5. Hirst, S. J., B. L. J. Webb, M. A. Giembycz, P. J. Barnes, and C. H. C. Twort. 1995. Inhibition of serum calf-stimulated proliferation of rabbit cultured tracheal smooth-muscle cells by selective inhibitors of protein kinase C and protein tyrosine kinase. Am. J. Respir. Cell Mol. Biol. 12: 149-161 [Abstract].
6.
Nishizuka, Y..
1992.
Intracellular signalling by hydrolysis of phospholipids
and activation of protein kinase C.
Science
258:
607-613
7. Hug, H., and T. F. Sarre. 1993. Protein kinase C isoenzymes: divergence in signal transduction? Biochem. J. 291: 329-343 .
8. Donnelly, R., K. X. F. Yang, M. B. Omary, S. Azhar, and J. L. Black. 1995. Expression of multiple isoenzymes of protein kinase C in airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 13: 253-256 [Abstract].
9.
Carlin, S.,
K. X. F. Yang,
R. Donnelly, and
J. L. Black.
1999.
Protein kinase
C isoforms in human airway smooth-muscle cells: a role for PKC-
in proliferation.
Am. J. Physiol.
276:
506-512
.
10. Webb, B. L. J., M. A. Lindsay, J. Seybold, N. J. Brand, M. H. Yacoub, E.-B. Hadda, P. J. Barnes, I. M. Adcock, and M. Giembycz. 1997. Identification of the protein kinase C isoenzymes in human lung and airways smooth muscle at the protein and mRNA level. Biochem. Pharmacol. 54: 199-205 [Medline].
11.
Togashi, H.,
C. A. Hirshman, and
C. W. Emala.
1997.
Qualitative immunoblot analysis of PKC isoforms expressed in airway smooth-muscle.
Am. J. Physiol.
272:
L603-L607
12.
Fukumoto, S.,
Y. Nishizawa,
M. Hosoi,
H. Koyama,
K. Yamakawa,
S. Ohno, and
H. Morii.
1997.
Protein kinase-
inhibits the proliferation of
vascular smooth-muscle cells by suppressing G1 cyclin expression.
J. Biol.
Chem.
272:
13816-13822
13.
Bandyopadhyay, G.,
M. L. Standaert,
L. Zhao,
B. Yu,
A. Avignon,
L. Galloway,
P. Karnam,
J. Moscat, and
R. V. Farese.
1997.
Activation of protein kinase C (
,
, and
) by insulin in 3T3/L1 cells.
J. Biol. Chem.
272:
2551-2558
14. Goldberg, M., and S. F. Steinberg. 1996. Tissue specific developmental regulation of protein kinase C isoforms. Biochem. Pharmacol. 51: 1089-1093 [Medline].
15. Hirai, S., Y. Izumi, K. Higa, K. Kaibuchi, K. Mizuno, S. Osada, K. Suzuki, and S. Ohno. 1994. Ras-dependent signal transduction is indispensable but not sufficient for the activation of AP1/Jun by PKC delta. EMBO J. 13: 2331-2340 [Medline].
16.
Mischak, H.,
J. Goodnight,
W. Kolch,
G. Martiny-Baron,
C. Schaechtle,
M. G. Kazanietz,
P. M. Blumberg,
J. H. Pierce, and
J. F. Mushinski.
1993.
Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence,
and tumorigenicity.
J. Biol. Chem.
268:
6090-6096
17.
Liao, D.-F.,
B. N. MoniaDean, and
B. C. Berk.
1997.
Protein kinase C-
mediates angiotensin II activation of ERK1/2 in vascular smooth-muscle
cells.
J. Biol. Chem.
272:
6146-6150
18. Lord, J. M., and J. Pongracz. 1995. Protein kinase C: a family of isoenzymes with a distinct role in pathogenesis. J. Clin. Path. 48: M57-M64 .
19. Johnson, P. R. A., D. Carey, C. L. Armour, and J. L. Black. 1995. PGE2 and heparin are antiproliferative mediators for human airway smooth-muscle cells in culture. Am. J. Physiol. 13: L514-L519 .
20. Goodnight, J., M. G Kazanietz, P. M. Blumberg, J. F. Mushinski, and H. Mischak. 1992. The cDNA sequence, expression pattern and protein characteristics of mouse protein kinase C-zeta. Gene 122: 305-311 [Medline].
21. Spessot, R., K. Inchley, T. M. Hupel, and S. Bacchetti. 1989. Cloning of the herpes simplex virus ICP4 gene in an adenovirus vector: effects on adenovirus gene expression and replication. Virology 168: 378-387 [Medline].
22. Graham, F. L., and L. Prevec. 1991. Manipulation of adenovirus vectors. In Methods in Molecular Biology, Vol. 7. E. J. Murray, editor. Humana Press, Inc., Totowa, NJ. 109-128.
23. Poronnik, P., L. M. O'Mullane, E. A. Harding, R. Greger, and D. I. Cook. 1998. Use of replication deficient adenoviruses to investigate the role of G proteins in Ca2+ signalling in epithelial cells. Cell Calcium 24: 97-103 [Medline].
24.
Hawker, K.,
P. R. A. Johnson,
J. M. Hughes, and
J. L. Black.
1998.
Interleukin-4 inhibits mitogen induced proliferation of human airway smooth muscle.
Am. J. Physiol.
275:
L469-L477
25.
Van Dijk, M. C. M.,
H. Hilkmann, and
W. J. Blitterswijk.
1997.
Platelet-
derived growth factor activation of mitogen-activated protein kinase depends on the sequential activation of phosphatidylcholine-specific phospholipase C, protein kinase C-
and Raf-1.
Biochem. J.
325:
303-307
.
26.
Limatola, C.,
D. Schapp,
W. H. Moolenaar, and
W. J. Blitterswijk.
1994.
Phosphatidic acid activation of protein kinase-C
overexpressed in COS
cells: comparison with other protein kinase C isotypes and other acidic lipids.
Biochem. J.
304:
1001-1008
.
27.
Le Good, J. A.,
W. H. Ziegler,
D. B. Parekh,
D. R. Alessi,
P. Cohen, and
P. J. Parker.
1998.
Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1.
Science
281:
2042-2045
28.
Diaz-Meco, M. T.,
E. Berra,
M. M. Municio,
L. Sanz,
J. Lozano,
I. Dominguez,
V. Diaz-Golpe,
M. T. Lain de Lera,
J. Alcami, and
C. V. Paya.
1993.
A dominant negative protein kinase C zeta subspecies blocks NF-kappa B
activation.
Mol. Cell. Biol.
13:
4770-4775
29.
Zacour, M. E., and
J. G. Martin.
2000.
Protein kinase C is involved in enhanced airway smooth-muscle growth in hyperresponsive rats.
Am. J. Physiol. (Lung Cell Mol. Physiol.)
278:
L59-L67
30.
Ammit, A. J.,
S. A. Kane, and
R. A. Panettieri.
1999.
Activation of K-p21ras
and N-p21ras, but not H-p21ras is necessary for mitogen-induced human airway smooth muscle proliferation.
Am. J. Respir. Cell Mol. Biol.
21:
719-727
31.
Berra, E.,
M. T. Diaz-Meco,
J. Lozano,
S. Frutos,
M. M. Municio,
P. Sanchez,
L. Sanz, and
J. Moscat.
1995.
Evidence for a role of MEK and MAPK
during signal transduction by protein kinase C
.
EMBO J.
14:
6157-6163
[Medline].
32.
Sajan, M. P.,
M. L. Standaert,
G. Bandyopadhyay,
M. J. Quon,
T. R. Burke Jr., and
R. V. Farese.
1999.
Protein kinase C-
and phosphoinoside-dependent protein kinase-1 are required for insulin-induced activation of ERK
in rat adipocytes.
J. Biol. Chem.
274:
30495-30500
33. Garcia-Paramio, P., Y. Cabrerizo, F. Bornancin, and P. J. Parker. 1998. The broad specificity of dominant inhibitory protein kinase C mutants infers a common step in phosphorylation. Biochem. J. 333: 631-636 .
34. Ishii, H., M. R. Jirousek, D. Koya, C. Takagi, P. Xia, A. Clermont, S.-E. Bursell, T. S. Kern, L. M. Ballas, W. F. Heath, L. E. Stramm, E. P. Feener, and G. L. King. 1996. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC inhibitor. Science 272: 728-731 [Abstract].
This article has been cited by other articles:
![]() |
M. D. Short, S. M. Fox, C. F. Lam, K. R. Stenmark, and M. Das Protein Kinase C{zeta} Attenuates Hypoxia-induced Proliferation of Fibroblasts by Regulating MAP Kinase Phosphatase-1 Expression Mol. Biol. Cell, April 1, 2006; 17(4): 1995 - 2008. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Datta, J. Li, R. Bhattacharya, L. Gasparian, E. Wang, and D. Mukhopadhyay Protein Kinase C {zeta} Transactivates Hypoxia-Inducible Factor {alpha} by Promoting Its Association with p300 in Renal Cancer Cancer Res., January 15, 2004; 64(2): 456 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Faisy, E. Naline, J.-L. Diehl, X. Emonds-Alt, T. Chinet, and C. Advenier In vitro sensitization of human bronchus by beta 2-adrenergic agonists Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L1033 - L1042. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hussain, J. W. Assender, M. Bond, L.-F. Wong, D. Murphy, and A. C. Newby Activation of Protein Kinase Czeta Is Essential for Cytokine-induced Metalloproteinase-1, -3, and -9 Secretion from Rabbit Smooth Muscle Cells and Inhibits Proliferation J. Biol. Chem., July 19, 2002; 277(30): 27345 - 27352. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |